No Problem PB, As we know Elmiron the oral PPS sold by J&J has a low absorption rate around 5%, so useless to treat OA in the current form, but does have mild blood thinning properties and has been used as a anticoagulant and to treat DVT in the past.
The patent suggests mixing normal doses of a coxib and pps has dual benefits of both drugs as detailed below in a excerpt of the 70 page patent application, reading through I can't see anywhere if they know 100% why this combo supposedly works, my guess is the absorption rate of the PPS is increased with the use of a coxib?
Pentosan polysulfate advantageously exhibits anti-thrombotic and other useful pharmacological activities not possessed by coxibs, and the use of PPS may also offset the known risk factors associated with the use of coxibs in elderly patients that may be pre-disposed to thrombosis, stroke or other cardiovascular events. PPS, however, is well known to have very low oral bioavailability and so has conventionally been administered parenterally. The invention, however, in at least some embodiments stems at least in part from the surprising observation that PPS administered orally in combination with a coxib can be highly effective in attenuating joint pain and joint stiffness
So what could the possible ramifications be:
If the oral formulation works and is not covered by PAR's patents then there goes the OA market, as I know that ever since my GP snapped off the needle in my arm during a tetanus shot I would go popping a couple of tablets a day every time than going the injectable route so PAR would have to shift focus to other diseases, but who's to say that oral would not work in other areas of treatment?. The cost of oral v IPPS would be extreme in favour of Oral I would think?
If PAR's patents do cover all oral treatments other than what Elmiron treats then that would be huge as Proteobiactives would have to cut a deal with PAR to get it to market.
That is only the start for PAR as the likes of Pfizer with Celebrex and also Merck could possibly reintroduce Vioxx to market with both combined with PPS, I'm not sure what size the market is for Celebrex, but I'm sure it would have a B at the end of it, I'm sure Mozz would be able to find that out in a second, but that market would increase substantially as GP's would feel far more comfortable subscribing the product to patients in the possible at risk category.
I think PAR will have a number of years with IPPS in the market before having to worry about the oral version coming to market.
So with further development down the track it could possibly be detrimental or massive for PAR. Attached patent pdf below, WO2019157560A1.pdf
Cheers BK14
PAR Price at posting:
$1.69 Sentiment: Buy Disclosure: Held
(20min delay)